Kev piav qhia
Cov mis mos molecular ntawm qhov nruab nrab no yog C13H10ClN3O2S, thiab nws qhov hnyav molecular yog 307.755.Nws cov qauv molecular meej ua rau kom muaj txiaj ntsig zoo thiab ua haujlwm siab ntawm tofacitinib.Yog li ntawd, tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo [2,3-d]pyrimidine yog ib qho tseem ceeb hauv kev lag luam kws tshuaj los muab kev kho mob zoo rau cov kab mob autoimmune.
Peb cov khoom yog tsim los ntawm cov txheej txheem ntawm lub xeev-of-the-art los xyuas kom meej qhov zoo tshaj plaws thiab sib xws.Peb nkag siab qhov tseem ceeb ntawm kev muaj kev ntseeg siab thiab ntshiab intermediates hauv kev tsim tshuaj, uas yog vim li cas peb tau cog lus los tswj cov qauv nruj tshaj plaws thaum peb cov txheej txheem tsim khoom.Peb tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo [2,3-d]pyrimidine tau ua tiav kev purity, ruaj khov thiab kev nyab xeeb kev ntsuam xyuas kom peb cov neeg muas zaub ntseeg siab nyob rau hauv kev ntseeg siab ntawm loj-scale synthesis ntawm tofacitinib.
Xaiv Peb
JDK muaj cov chaw tsim khoom thawj zaug thiab cov cuab yeej tswj kev ua haujlwm zoo, uas ua kom muaj kev ruaj khov ntawm API intermediates.Pab neeg tshaj lij paub tseeb R & D ntawm cov khoom.Tawm tsam ob qho tib si, peb tab tom nrhiav rau CMO & CDMO hauv kev lag luam hauv tsev thiab thoob ntiaj teb.